Related Experiment Video
Updated: Aug 6, 2026
Diagnosis of Hirschsprung's Disease by Immunostaining Rectal Suction Biopsies for Calretinin, S100 Protein and Protein Gene Product 9.5
Published on: April 26, 2019
Diagnosis and management of gastrointestinal SMARCA4-deficient undifferentiated tumors
John Wang1, Omar Elghawy2, Brett Kurpiel3
1University of Virginia Cancer Center, Charlottesville, VA, USA.
Abstract:
SMARCA4-deficient undifferentiated tumors are a rare clinical entity with an aggressive clinical course, poor prognosis, and no standard-of-care therapeutic approach. These have most frequently been documented in the lung and thoracic cavity. There is a growing body of evidence for the role of immunotherapy in SMARCA4-deficient lung cancer, a disease process that historically does very poorly with cytotoxic chemotherapy alone. We present three cases where the primary tumors were instead found within the gastrointestinal system: two originating from the small bowel and one from the esophagus. In all three cases, clinical response was seen with pembrolizumab therapy, with two of the three patients receiving long-term benefit. Our series suggests that anti-PD1 immunotherapy may have promising efficacy for undifferentiated carcinomas of the gastrointestinal tract with SMARCA4 deficiency.
Insights
SMARCA4-deficient undifferentiated tumors in the gastrointestinal tract show promise with anti-PD1 immunotherapy. This approach offers potential long-term benefit for patients with this rare and aggressive cancer.
Area of Science:
- Oncology
- Medical Research
Background:
- SMARCA4-deficient undifferentiated tumors are rare, aggressive, and lack standard treatments.
- These tumors are typically found in the lung and thoracic cavity.
- Immunotherapy shows promise for SMARCA4-deficient lung cancer, outperforming chemotherapy.
Purpose of the Study:
- To investigate the efficacy of anti-PD1 immunotherapy in gastrointestinal SMARCA4-deficient undifferentiated tumors.
- To present case studies of patients treated with pembrolizumab for these rare tumors.
Main Methods:
- Case series analysis of three patients with primary gastrointestinal SMARCA4-deficient undifferentiated tumors.
- Treatment administered included pembrolizumab (anti-PD1 immunotherapy).
- Clinical response and long-term benefit were assessed.
Main Results:
- All three patients exhibited a clinical response to pembrolizumab therapy.
- Two out of three patients experienced long-term benefit from the immunotherapy.
- Tumor origins included the small bowel (two cases) and esophagus (one case).
Conclusions:
- Anti-PD1 immunotherapy, specifically pembrolizumab, may be effective for undifferentiated gastrointestinal carcinomas with SMARCA4 deficiency.
- This immunotherapy offers a potential therapeutic option for this rare and aggressive cancer subtype.
- Further research is warranted to confirm these findings in a larger patient cohort.
Related Concept Videos
01:21Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:30Serum Laboratory Studies, Stool Test, Breath Test
01:26Imaging Studies III: Gastrointestinal Motility Studies and Virtual Colonoscopy
Radionuclide Testing
Radionuclide testing is a sophisticated medical technique for assessing gastrointestinal motility. It focuses on gastric emptying and colonic transit time. Radioactive markers track the movement of food through the digestive system, providing insights into gastrointestinal disorders.
In gastric emptying studies, a meal's liquid and solid...